戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 h 5 to 10 mm in 4 reference patients without structural disease.
2 is of ischemic heart disease had surgery for structural disease.
3  validate this strategy in eyes with macular structural disease.
4  blood pressure control promote long-term LV structural disease.
5 ncement scar, indicating a relationship with structural disease.
6 pathogenesis of sex- and age-related macular structural diseases.
7   We extended its application to hearts with structural disease and examined its ability to detect an
8 was no association between progressive RV/LV structural disease and newly developed ECG TFC.
9 nd genotype-positive relatives without overt structural disease and VA at first evaluation into 3 gro
10    Alarm symptoms suggest the possibility of structural disease, but do not necessarily negate a diag
11 icular arrhythmia; proband status; extent of structural disease; cardiac syncope; male sex; the prese
12 ence of locoregional recurrent or persistent structural disease, distant metastases, or death from th
13 cular measure that may aid the prediction of structural disease evolution and represents a potential
14                                              Structural disease found infrequently in patients with I
15 ordance between symptoms and the severity of structural disease has not been explained.
16  that electrical abnormalities precede overt structural disease in arrhythmogenic right ventricular c
17                     To identify subthreshold structural disease in normal-appearing lung regions in s
18                        Background Imaging of structural disease in osteoarthritis has traditionally r
19                             The incidence of structural disease in patients with concerning symptoms
20 -can induce cardiomyopathy in the absence of structural disease in the heart.
21 reatening arrhythmias even in the absence of structural disease.It is believed that mutations in desm
22 h CF, lung clearance index is insensitive to structural disease (kappa = -0.03 [95% confidence interv
23                            Historically, the structural disease model proposed mechanical defects of
24 e evaluated the efficacy of these agents for structural disease modification.
25 rdial leads, V1-V3 (unrelated to ischemia or structural disease), normal QT intervals, apparent right
26 es, aortopathies, hypercholesterolemias, and structural diseases of the heart and great vessels.
27                                              Structural disease persistence or recurrence, distant me
28                                      Rate of structural disease progression, symmetry between eyes, a
29 regurgitation is an independent predictor of structural disease progression, which may be exacerbated
30 h as the prognostic value of cardiac MRI and structural disease progression, while discussing the lat
31  in the disease course to arrest and prevent structural disease progression.
32 stry were retrospectively compared to assess structural disease progression.